Current Issues in Molecular Biology, Journal Year: 2025, Volume and Issue: 47(3), P. 153 - 153
Published: Feb. 26, 2025
Metastatic endometrial cancer continues to be a common cause of death as 2024, even after maximal use all currently available standard treatments. To address this problem metastatic generally in 2025, the drug repurposing movement within oncology identifies medicines general medical that have clinical or preclinical experimental data indicating they interfere with inhibit specific growth driving element identified given cancer. The also uses from large scale vitro screens thousands drugs, looking for simple empirical inhibition type. This paper outlines showing five drugs practice meet these evidence criteria growth, EC5 regimen. regimen osteoporosis treatment drug, alendronate; analgesic celecoxib; antifungal itraconazole; sleep aid, ramelteon; and cholesterol lowering simvastatin. Side effects seen are usually minimal easily tolerated by patients.
Language: Английский